South Australian Medicines Evaluation Panel (SAMEP)

The South Australian Medicines Evaluation Panel (SAMEP) was established in 2011 as an expert standing committee of the South Australian Medicines Advisory Committee (SAMAC) to ensure that all public hospitals provide a consistent approach to the management of High Cost Medicines. The main role of SAMEP is to review the use of High Cost Medicines, for a list of medicines being reviewed or previously reviewed, see the High Cost Medicine reviews page. 

SAMEP were the winners of the 2014 SA Health Award "Excellence in Non-clinical Services"

Their role

The role of SAMEP includes:

  • Evaluating the safety, the clinical efficacy and cost-effectiveness of high cost medicines proposed for inclusion in the Statewide High Cost Medicines Formulary.
  • Initiating reviews to evaluate the safety and effectiveness of high cost medicines which are not registered for use within Australia for the purpose of providing guidance to local hospital drug committees with regards to consideration of individual patient use requests.
  • Making recommendations to SAMAC with regards to which high cost medicines should be made available in South Australian public hospitals and on the potential place in therapy of these medicines.
  • Facilitating the monitoring of high cost medicine use in South Australian public hospitals.

Meeting dates

SAMEP meet every two months to review high cost medicine formulary applications. The next scheduled meetings for 2024 are:

  • 31 January
  • 27 March
  • 22 May
  • 17 July
  • 11 September
  • 6 November


Chaired by Dr Tilenka Thynne, SAMEP includes specialist clinicians, pharmacists, health economists, an ethicist and a consumer representative. Members include:

  • Dr Tilenka Thynne, Clinical Pharmacologist and Endocrinologist, Flinders Medical Centre
  • Dr Damian Clark, Paediatric Neurologist, Women's and Children's Hospital
  • Dr Ganessan Kichenadasse, Consultant, Medical Oncology, Flinders Medical Centre
  • Ass Prof Michael Ward, Professorial Lead: Pharmacy and Biosciences, Discipline Leader: Pharmacy Education, UniSA Clinical and Health Sciences
  • Ms Joy Gailer, Clinical Pharmacist, Drug and Therapeutics Information Service, Repatriation General Hospital
  • Ms Catherine Booth, Clinical Pharmacist, Women's and Children's Hospital
  • Ass Prof Benjamin Reddi, Staff Specialist, Intensive Care Unit, Royal Adelaide Hospital
  • Ms Naomi Burgess Director, Medicines & Technology Programs, SA Health (ex officio)
  • Ms Camille Schubert, Health Economist, Adelaide Health technology Assessment, University of Adelaide
  • Ass Prof David Ross, Department of Haematology and Bone Marrow Transplantation, The Royal Adelaide Hospital
  • Mr David Tamblyn, Evaluator, Adelaide Health Technology Assessment, University of Adelaide
  • Prof Brett Bowden, Consumer Representative
  • Dr Agnes Vitry, Senior Pharmacist, Executive Officer, Medicines & Technology Programs, SA Health
  • Dr Joshua Inglis, Clinical Pharmacology Registrar, Flinders Medical Centre
  • Ms Anna Fletcher, Senior Pharmacist,  Haematology, Royal Adelaide Hospital
  • Ms Celine Chee, Senior Pharmacist, Executive Officer NAHLN DTC
  • Dr David Hunter, Senior Lecturer, University of Adelaide
  • Dr Despina Papps, Medical Administration Registrar, CAHLN
  • Dr Dylan Mordaunt, Clinical Director, Women’s and Children’s Division, Flinders Medical Centre


All enquiries regarding the High Cost Medicines policy or SAMEP should be directed to